GILEAD SCIENCES (GIS HM) stock market data APIs
€94.6769
-0.36(-0.4%)
as of July 1, 2025
Try our APIs with
free plan!
GILEAD SCIENCES Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GIS.HM.
Prev. Close
94.6769
Open
94.3123
High
94.6769
Low
94.3123
52 wk Range
59.3009-109.3078
Market Cap
78 028 M
Dividends (Yield)
0.0266
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GILEAD SCIENCES data using free add-ons & libraries
Get GILEAD SCIENCES Fundamental Data
GILEAD SCIENCES Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GILEAD SCIENCES News
New
Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 | Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth
Company Logo The global chronic hepatitis B market is experiencing growth due to breakthroughs in diagnosis and treatment, including gene-editing and immune modulation therapies. With therapies advan...
Gilead extends gains after Supreme Court upheld an Obamacare provision
Investing.com -- The U.S. Supreme Court upheld a provision of the Affordable Care Act requiring insurers to cover preventive services, such as HIV prevention and cancer screenings, at no additional co...
This firm represents one of investing’s toughest moral debates
While many big drug companies do amazing things for humanity, they’re also often vilified for profiteering from their work. This month, New York-listed Gilead Sciences has, not for the first time, r...
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement w...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
